Menogaril, an anthracycline compound with a novel mechanism of action

Cellular pharmacology

Konstanty Wierzba, Yoshikazu Sugimoto, Ken ichi Matsuo, Toshiyuki Toko, Setsuo Takeda, Yuji Yamada, Shigeru Tsukagoshi

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Menogaril, an anthracycline compound possessing a significant antitumor activity after both po and iv administration, has been introduced into clinical trials. However, its mechanisms of action has not been clarified yet. This study revealed that its cytotoxicity correlated very well with the inhibition of macromolecular synthesis, indicating the involvement of interaction with DNA. The spectrophotometric study showed a weaker binding of this compound to calf thymus DNA when compared to that of doxorubicin (adriamycin). Despite the lower binding affinity of menogaril to DNA, pronounced DNA cleavage was observed in an intact cell system, indicating that the character of the interaction with DNA is different from intercalation. In contrast to doxorubicin, menogaril is extensively localized in the cytoplasm. The cytoplasmic localization prompted us to study its effect on cytoskeleton proteins. It was found that menogaril inhibited the initial polymerization rate of tubulin, indicating a possible contribution of this process to the overall cytotoxicity of menogaril.

Original languageEnglish
Pages (from-to)842-849
Number of pages8
JournalJapanese Journal of Cancer Research
Volume81
Issue number8
Publication statusPublished - 1990 Aug
Externally publishedYes

Fingerprint

Menogaril
Anthracyclines
Pharmacology
Doxorubicin
DNA
DNA Cleavage
Tubulin
Cytoskeleton
Polymerization
Cytoplasm
Clinical Trials

Keywords

  • Anthracycline compound
  • Interaction with DNA
  • Menogaril
  • Microtubular system

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Wierzba, K., Sugimoto, Y., Matsuo, K. I., Toko, T., Takeda, S., Yamada, Y., & Tsukagoshi, S. (1990). Menogaril, an anthracycline compound with a novel mechanism of action: Cellular pharmacology. Japanese Journal of Cancer Research, 81(8), 842-849.

Menogaril, an anthracycline compound with a novel mechanism of action : Cellular pharmacology. / Wierzba, Konstanty; Sugimoto, Yoshikazu; Matsuo, Ken ichi; Toko, Toshiyuki; Takeda, Setsuo; Yamada, Yuji; Tsukagoshi, Shigeru.

In: Japanese Journal of Cancer Research, Vol. 81, No. 8, 08.1990, p. 842-849.

Research output: Contribution to journalArticle

Wierzba, K, Sugimoto, Y, Matsuo, KI, Toko, T, Takeda, S, Yamada, Y & Tsukagoshi, S 1990, 'Menogaril, an anthracycline compound with a novel mechanism of action: Cellular pharmacology', Japanese Journal of Cancer Research, vol. 81, no. 8, pp. 842-849.
Wierzba, Konstanty ; Sugimoto, Yoshikazu ; Matsuo, Ken ichi ; Toko, Toshiyuki ; Takeda, Setsuo ; Yamada, Yuji ; Tsukagoshi, Shigeru. / Menogaril, an anthracycline compound with a novel mechanism of action : Cellular pharmacology. In: Japanese Journal of Cancer Research. 1990 ; Vol. 81, No. 8. pp. 842-849.
@article{1e57407a731f41c8b66e787aea91a135,
title = "Menogaril, an anthracycline compound with a novel mechanism of action: Cellular pharmacology",
abstract = "Menogaril, an anthracycline compound possessing a significant antitumor activity after both po and iv administration, has been introduced into clinical trials. However, its mechanisms of action has not been clarified yet. This study revealed that its cytotoxicity correlated very well with the inhibition of macromolecular synthesis, indicating the involvement of interaction with DNA. The spectrophotometric study showed a weaker binding of this compound to calf thymus DNA when compared to that of doxorubicin (adriamycin). Despite the lower binding affinity of menogaril to DNA, pronounced DNA cleavage was observed in an intact cell system, indicating that the character of the interaction with DNA is different from intercalation. In contrast to doxorubicin, menogaril is extensively localized in the cytoplasm. The cytoplasmic localization prompted us to study its effect on cytoskeleton proteins. It was found that menogaril inhibited the initial polymerization rate of tubulin, indicating a possible contribution of this process to the overall cytotoxicity of menogaril.",
keywords = "Anthracycline compound, Interaction with DNA, Menogaril, Microtubular system",
author = "Konstanty Wierzba and Yoshikazu Sugimoto and Matsuo, {Ken ichi} and Toshiyuki Toko and Setsuo Takeda and Yuji Yamada and Shigeru Tsukagoshi",
year = "1990",
month = "8",
language = "English",
volume = "81",
pages = "842--849",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Menogaril, an anthracycline compound with a novel mechanism of action

T2 - Cellular pharmacology

AU - Wierzba, Konstanty

AU - Sugimoto, Yoshikazu

AU - Matsuo, Ken ichi

AU - Toko, Toshiyuki

AU - Takeda, Setsuo

AU - Yamada, Yuji

AU - Tsukagoshi, Shigeru

PY - 1990/8

Y1 - 1990/8

N2 - Menogaril, an anthracycline compound possessing a significant antitumor activity after both po and iv administration, has been introduced into clinical trials. However, its mechanisms of action has not been clarified yet. This study revealed that its cytotoxicity correlated very well with the inhibition of macromolecular synthesis, indicating the involvement of interaction with DNA. The spectrophotometric study showed a weaker binding of this compound to calf thymus DNA when compared to that of doxorubicin (adriamycin). Despite the lower binding affinity of menogaril to DNA, pronounced DNA cleavage was observed in an intact cell system, indicating that the character of the interaction with DNA is different from intercalation. In contrast to doxorubicin, menogaril is extensively localized in the cytoplasm. The cytoplasmic localization prompted us to study its effect on cytoskeleton proteins. It was found that menogaril inhibited the initial polymerization rate of tubulin, indicating a possible contribution of this process to the overall cytotoxicity of menogaril.

AB - Menogaril, an anthracycline compound possessing a significant antitumor activity after both po and iv administration, has been introduced into clinical trials. However, its mechanisms of action has not been clarified yet. This study revealed that its cytotoxicity correlated very well with the inhibition of macromolecular synthesis, indicating the involvement of interaction with DNA. The spectrophotometric study showed a weaker binding of this compound to calf thymus DNA when compared to that of doxorubicin (adriamycin). Despite the lower binding affinity of menogaril to DNA, pronounced DNA cleavage was observed in an intact cell system, indicating that the character of the interaction with DNA is different from intercalation. In contrast to doxorubicin, menogaril is extensively localized in the cytoplasm. The cytoplasmic localization prompted us to study its effect on cytoskeleton proteins. It was found that menogaril inhibited the initial polymerization rate of tubulin, indicating a possible contribution of this process to the overall cytotoxicity of menogaril.

KW - Anthracycline compound

KW - Interaction with DNA

KW - Menogaril

KW - Microtubular system

UR - http://www.scopus.com/inward/record.url?scp=0025046376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025046376&partnerID=8YFLogxK

M3 - Article

VL - 81

SP - 842

EP - 849

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 8

ER -